Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04028063

Recruitment Status : Not yet recruiting

First Posted : July 22, 2019

Last Update Posted : November 19, 2019

See Contacts and Locations

Sponsor:

Collaborators:

National Cancer Institute (NCI)

Agenus Inc.

Information provided by (Responsible Party):

University of Colorado, Denver

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Not yet recruiting
Estimated Primary Completion Date :	November 24, 2021
Estimated Study Completion Date :	November 2022

To Top